January 7, 2021 – Ontario, Canada – SignPost Cancer Dx Inc. (“SignPost” or “company”), a company developing an advanced molecular diagnostic test to identify invasive breast cancer, announced today that Mr. Peter Blaney, Chief Executive Officer, will present at the 2021 BioConnect Conference hosted by H.C. Wainwright. Registered attendees can access the recorded presentation on-demand (24×7) for the duration of the conference.
| Conference Date: | January 11-14, 2021 (Monday-Thursday) |
| Presentation On-Demand: | Starting 6:00am ET – Monday, January 11, 2021 |
| Registration: | https://hcwevents.com/ |
Mr. Blaney will highlight the company’s lead product, BreastDefense, a molecular diagnostic test to identify invasive breast cancers, from Stage 1-4, with 98.5% accuracy and the company’s strategy going forward.
SignPost will be available for virtual 1:1 meetings both during and after the BioConnect Conference. Please contact Jennifer K. Zimmons, Ph.D. [email protected] 917.214.3514 for scheduling.
About SignPost Cancer Dx Inc.
SignPost is a company developing an advanced molecular diagnostic test, BreastDefense, to identify invasive breast cancers, from Stage 1-4, with 98.5% accuracy. BreastDefense is being developed in both tissue and liquid biopsy versions. SignPost was founded and is managed by Induran Ventures, a Venture Philanthropy General Partnership which strives to achieve both outsized returns and massive social impact through its projects. For more information, please visit www.signpostcancerdx.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
SignPost Cancer Dx Inc.
Peter Blaney
Chief Executive Officer
SignPost Cancer Dx Inc.
Tel: +1 613.532.1290
Email: [email protected]
Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514
Email: [email protected]
Source: SignPost Cancer Dx Inc.
###